Sustained virological response rates with direct‐acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expa...
Uloženo v:
| Vydáno v: | Journal of Virus Eradication Ročník 5; číslo 3; s. 138 - 144 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Mediscript Ltd
18.09.2019
Elsevier |
| Témata: | |
| ISSN: | 2055-6640, 2055-6659 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals
non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HCV genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity.
Twenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV.
Of the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%-100% in black individuals and 87.5%-100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1%
97.3%). Baseline characteristics did not affect SVR12 for the two groups. Of the 742 subjects with both HCV GT1 and HIV, 243 (32.7%) were black: SVR12 was 89.5%-100% in black individuals and 94.4%-100% in non-black individuals. In pooled analyses for HCV GT1/HIV co-infection, black individuals had a 4% (95% confidence interval -7.7% to 0.3%) lower SVR12 than non-black individuals (93.4%
97.0%). This difference was driven by ION-4 in which study SVR12 was approximately 10% lower for black than for non-black individuals (89.5%
99.1%). Baseline characteristics did not affect SVR12 for the two groups.
No notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV. |
|---|---|
| AbstractList | Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HCV genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity.OBJECTIVESUnder representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HCV genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity.Twenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV.METHODSTwenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV.Of the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%-100% in black individuals and 87.5%-100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1% vs 97.3%). Baseline characteristics did not affect SVR12 for the two groups. Of the 742 subjects with both HCV GT1 and HIV, 243 (32.7%) were black: SVR12 was 89.5%-100% in black individuals and 94.4%-100% in non-black individuals. In pooled analyses for HCV GT1/HIV co-infection, black individuals had a 4% (95% confidence interval -7.7% to 0.3%) lower SVR12 than non-black individuals (93.4% vs 97.0%). This difference was driven by ION-4 in which study SVR12 was approximately 10% lower for black than for non-black individuals (89.5% vs 99.1%). Baseline characteristics did not affect SVR12 for the two groups.RESULTSOf the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%-100% in black individuals and 87.5%-100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1% vs 97.3%). Baseline characteristics did not affect SVR12 for the two groups. Of the 742 subjects with both HCV GT1 and HIV, 243 (32.7%) were black: SVR12 was 89.5%-100% in black individuals and 94.4%-100% in non-black individuals. In pooled analyses for HCV GT1/HIV co-infection, black individuals had a 4% (95% confidence interval -7.7% to 0.3%) lower SVR12 than non-black individuals (93.4% vs 97.0%). This difference was driven by ION-4 in which study SVR12 was approximately 10% lower for black than for non-black individuals (89.5% vs 99.1%). Baseline characteristics did not affect SVR12 for the two groups.No notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV.CONCLUSIONNo notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV. Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HCV genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity. Twenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV. Of the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%-100% in black individuals and 87.5%-100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1% 97.3%). Baseline characteristics did not affect SVR12 for the two groups. Of the 742 subjects with both HCV GT1 and HIV, 243 (32.7%) were black: SVR12 was 89.5%-100% in black individuals and 94.4%-100% in non-black individuals. In pooled analyses for HCV GT1/HIV co-infection, black individuals had a 4% (95% confidence interval -7.7% to 0.3%) lower SVR12 than non-black individuals (93.4% 97.0%). This difference was driven by ION-4 in which study SVR12 was approximately 10% lower for black than for non-black individuals (89.5% 99.1%). Baseline characteristics did not affect SVR12 for the two groups. No notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV. Objectives: Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals. HCV trials submitted to the Food and Drug Administration (2013–2017) to support approval or to expand an indication of 12-week interferon-free DAA regimens with or without ribavirin to treat HCV genotype 1 (GT1) infection were pooled to explore efficacy comparisons by ethnicity. Methods: Twenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV. Results: Of the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%–100% in black individuals and 87.5%–100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1% vs 97.3%). Baseline characteristics did not affect SVR12 for the two groups. Of the 742 subjects with both HCV GT1 and HIV, 243 (32.7%) were black: SVR12 was 89.5%–100% in black individuals and 94.4%–100% in non-black individuals. In pooled analyses for HCV GT1/HIV co-infection, black individuals had a 4% (95% confidence interval −7.7% to 0.3%) lower SVR12 than non-black individuals (93.4% vs 97.0%). This difference was driven by ION-4 in which study SVR12 was approximately 10% lower for black than for non-black individuals (89.5% vs 99.1%). Baseline characteristics did not affect SVR12 for the two groups. Conclusion: No notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV. |
| Author | Valappil, Thamban Struble, Kimberly Mishra, Poonam Qi, Karen Price, Dionne Murray, Jeffrey Chan-Tack, Kirk Connelly, Sarah Birnkrant, Debra |
| Author_xml | – sequence: 1 givenname: Kimberly surname: Struble fullname: Struble, Kimberly – sequence: 2 givenname: Kirk surname: Chan-Tack fullname: Chan-Tack, Kirk – sequence: 3 givenname: Karen surname: Qi fullname: Qi, Karen – sequence: 4 givenname: Thamban surname: Valappil fullname: Valappil, Thamban – sequence: 5 givenname: Sarah surname: Connelly fullname: Connelly, Sarah – sequence: 6 givenname: Poonam surname: Mishra fullname: Mishra, Poonam – sequence: 7 givenname: Dionne surname: Price fullname: Price, Dionne – sequence: 8 givenname: Jeffrey surname: Murray fullname: Murray, Jeffrey – sequence: 9 givenname: Debra surname: Birnkrant fullname: Birnkrant, Debra |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31700657$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkkluVDEQhp9QEBnIEUBehkVDeXgTSJFQK5BIkVgE2Fq2X7nj8NpubHdQ7zgCB-B0nAT3QIuwYVVW1V9flVz_cXXgg8eqekbhJQXavLphUNeTphFwxuAFBxB8Qh9VR7t03R_s3wIOq9OUnIYaWi4oo0-qQ05bgKZuj6qfN8uUlfM4kHsXwxhmzqiRREyL4BOSqDIm8s3lWzK4iCb_-v5Dmez8jCifXelRYyLOEz0q84Wkpb4rol3H5fQzmaEPebVAQovKlpoL_jVJq5RxrrIzBaPGVXKJBEvM6Pxmfo6ucJ9Wj20JeLqLJ9Wndxcfp5eT6w_vr6ZvrydGtG2eGIUKOqt7HHrDdDPojg-t7nRjWwuNAaa7WhhWc9BCU65AtHwQXCvK-KA0P6muttwhqDu5iG6u4koG5eQmEeJMqlh2HVGi6oxAGHqLVNBG98AsCAPUtj1jlhfW-Za1WOo5DgZ9Ll_0APqw4t2tnIV72XS0obQrgLMdIIavS0xZzl0yOI7KY1gmyTjlvO36mhbp879n7Yf8OW8R1FuBiSGliHYvoSDXTpIbJ8m1TSQDuXGSXIPf_NNnXFbr05WV3fif7t9nXtOc |
| CitedBy_id | crossref_primary_10_1111_jvh_13901 crossref_primary_10_1093_ofid_ofaa044 crossref_primary_10_1002_hep_31742 |
| Cites_doi | 10.1056/NEJMoa1501315 10.1038/nature08309 10.1016/j.cgh.2011.03.004 10.1002/hep.29308 10.7326/M16-2575 10.1002/hep.29057 10.1002/hep.28334 10.7326/M13-1829 10.1093/cid/cix260 10.1002/hep.28625 10.1001/jama.2012.144878 10.1093/cid/cix111 10.1093/cid/cix117 10.1086/644771 10.1001/jama.2015.1328 10.1002/hep.29642 10.1002/hep.27978 10.1016/S1473-3099(15)00485-5 10.1093/ofid/ofx062 10.3851/IMP3117 10.1093/ofid/ofx264 10.1002/hep.28901 10.1056/NEJMoa1503153 10.1002/hep.510300319 10.7326/0003-4819-158-9-201305070-00604 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd. 2019 The Authors. published by Mediscript Ltd |
| Copyright_xml | – notice: 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd. – notice: 2019 The Authors. published by Mediscript Ltd |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/S2055-6640(20)30043-1 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2055-6659 |
| EndPage | 144 |
| ExternalDocumentID | oai_doaj_org_article_ea8c4e0d9fe1416b902f04c01f7922f3 PMC6816118 31700657 10_1016_S2055_6640_20_30043_1 |
| Genre | Editorial Commentary |
| GroupedDBID | AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION M~E NPM 7X8 0R~ 5PM AAEDW AALRI AAXUO AAYWO ACVFH ADBBV ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AITUG AKBMS AKRWK AKYEP AMRAJ AOIJS EBS FDB GROUPED_DOAJ HYE OK1 RPM W2D |
| ID | FETCH-LOGICAL-c477t-caea08fb9ed9c2b6db83d7b8b6f7f06c02b854c2530b4b13a0473d43ba123dab3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000494965700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2055-6640 |
| IngestDate | Fri Oct 03 12:28:43 EDT 2025 Thu Aug 21 14:12:48 EDT 2025 Wed Oct 01 14:06:36 EDT 2025 Wed Jun 21 02:32:03 EDT 2023 Tue Nov 18 22:21:28 EST 2025 Wed Nov 05 20:51:51 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | clinical trial hepatitis C Food and Drug Administration |
| Language | English |
| License | 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd. This is an open access article published under the terms of a Creative Commons License. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-caea08fb9ed9c2b6db83d7b8b6f7f06c02b854c2530b4b13a0473d43ba123dab3 |
| Notes | SourceType-Scholarly Journals-1 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1 Shared first authorship. |
| OpenAccessLink | https://doaj.org/article/ea8c4e0d9fe1416b902f04c01f7922f3 |
| PMID | 31700657 |
| PQID | 2313378951 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ea8c4e0d9fe1416b902f04c01f7922f3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6816118 proquest_miscellaneous_2313378951 pubmed_primary_31700657 crossref_primary_10_1016_S2055_6640_20_30043_1 crossref_citationtrail_10_1016_S2055_6640_20_30043_1 |
| PublicationCentury | 2000 |
| PublicationDate | 20190918 |
| PublicationDateYYYYMMDD | 2019-09-18 |
| PublicationDate_xml | – month: 9 year: 2019 text: 20190918 day: 18 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of Virus Eradication |
| PublicationTitleAlternate | J Virus Erad |
| PublicationYear | 2019 |
| Publisher | Mediscript Ltd Elsevier |
| Publisher_xml | – name: Mediscript Ltd – name: Elsevier |
| References | Kirk (10.1016/S2055-6640(20)30043-1_bb0195) 2013; 158 Collins (10.1016/S2055-6640(20)30043-1_bb0205) 2018; 5 van der Meer (10.1016/S2055-6640(20)30043-1_bb0035) 2012; 308 Zepatier (package insert) (10.1016/S2055-6640(20)30043-1_bb0145) 2017 Harvoni (package insert) (10.1016/S2055-6640(20)30043-1_bb0150) 2017 Reddy (10.1016/S2055-6640(20)30043-1_bb0045) 1999; 30 Bhattacharya (10.1016/S2055-6640(20)30043-1_bb0115) 2017; 64 Chen (10.1016/S2055-6640(20)30043-1_bb0200) 2009; 49 Backus (10.1016/S2055-6640(20)30043-1_bb0030) 2011; 9 O’Brien (10.1016/S2055-6640(20)30043-1_bb0070) 2017; 65 Patel (10.1016/S2055-6640(20)30043-1_bb0130) 2017; 4 Centers for Disease Control and Prevention (10.1016/S2055-6640(20)30043-1_bb0015) 2018 Daklinza (package insert) (10.1016/S2055-6640(20)30043-1_bb0140) 2017 Wilder (10.1016/S2055-6640(20)30043-1_bb0040) 2016; 108 Wyles (10.1016/S2055-6640(20)30043-1_bb0110) 2017; 65 Falade-Nwulia (10.1016/S2055-6640(20)30043-1_bb0090) 2017; 166 Platt (10.1016/S2055-6640(20)30043-1_bb0025) 2016; 16 Backus (10.1016/S2055-6640(20)30043-1_bb0075) 2016; 64 Victrelis® (package insert) (10.1016/S2055-6640(20)30043-1_bb0055) 2017 Wilder (10.1016/S2055-6640(20)30043-1_bb0085) 2016; 63 Wyles (10.1016/S2055-6640(20)30043-1_bb0105) 2015; 373 Sikavi (10.1016/S2055-6640(20)30043-1_bb0135) 2018; 67 Vosevi (package insert) (10.1016/S2055-6640(20)30043-1_bb0175) 2017 Edlin (10.1016/S2055-6640(20)30043-1_bb0020) 2015; 62 Incivek® (package insert) (10.1016/S2055-6640(20)30043-1_bb0060) 2013 Mavyret (package insert) (10.1016/S2055-6640(20)30043-1_bb0155) 2017 Burton (10.1016/S2055-6640(20)30043-1_bb0120) 2017; 64 Epclusa (package insert) (10.1016/S2055-6640(20)30043-1_bb0170) 2017 Struble (10.1016/S2055-6640(20)30043-1_bb0180) 2017 Su (10.1016/S2055-6640(20)30043-1_bb0065) 2017; 65 World Health Organization (WHO) (10.1016/S2055-6640(20)30043-1_bb0010) 2017 Viekira Pak (package insert) (10.1016/S2055-6640(20)30043-1_bb0160) 2017 Ge (10.1016/S2055-6640(20)30043-1_bb0050) 2009; 461 Chung (10.1016/S2055-6640(20)30043-1_bb0185) 2018 Lo Re (10.1016/S2055-6640(20)30043-1_bb0190) 2014; 160 Sulkowski (10.1016/S2055-6640(20)30043-1_bb0100) 2015; 313 Falade-Nwulia (10.1016/S2055-6640(20)30043-1_bb0125) 2017; 66 Backus (10.1016/S2055-6640(20)30043-1_bb0080) 2017; 22 Naggie (10.1016/S2055-6640(20)30043-1_bb0095) 2015; 373 Olysio (package insert) (10.1016/S2055-6640(20)30043-1_bb0165) 2017 |
| References_xml | – year: 2013 ident: 10.1016/S2055-6640(20)30043-1_bb0060 – volume: 373 start-page: 705 year: 2015 ident: 10.1016/S2055-6640(20)30043-1_bb0095 article-title: Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1501315 – volume: 461 start-page: 399 year: 2009 ident: 10.1016/S2055-6640(20)30043-1_bb0050 article-title: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance publication-title: Nature doi: 10.1038/nature08309 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0140 – volume: 9 start-page: 509 year: 2011 ident: 10.1016/S2055-6640(20)30043-1_bb0030 article-title: A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2011.03.004 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0150 – volume: 66 start-page: 1402 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0125 article-title: High hepatitis C cure rates among black and non-blacks human immunodeficiency virus-infected adults in an urban center publication-title: Hepatology doi: 10.1002/hep.29308 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0010 publication-title: Global hepatitis report, 2017 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0175 – volume: 166 start-page: 637 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0090 article-title: Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review publication-title: Ann Intern Med doi: 10.7326/M16-2575 – volume: 65 start-page: 2124 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0070 article-title: Race or genetic makeup for hepatitis C virus treatment decisions? publication-title: Hepatology doi: 10.1002/hep.29057 – volume: 63 start-page: 437 year: 2016 ident: 10.1016/S2055-6640(20)30043-1_bb0085 article-title: Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data publication-title: Hepatology doi: 10.1002/hep.28334 – volume: 160 start-page: 369 year: 2014 ident: 10.1016/S2055-6640(20)30043-1_bb0190 article-title: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-mono-infected patients: a cohort study publication-title: Ann Intern Med doi: 10.7326/M13-1829 – volume: 108 start-page: 24 year: 2016 ident: 10.1016/S2055-6640(20)30043-1_bb0040 article-title: A systematic review of race and ethnicity in hepatitis C clinical trial enrollment publication-title: J Natl Med Assoc – volume: 65 start-page: 6 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0110 article-title: Sofosbuvir and velpatasvir for the treatment of HCV in patients coinfected with HIV-1: an open-label, phase 3 study publication-title: Clin Infect Dis doi: 10.1093/cid/cix260 – volume: 64 start-page: 405 year: 2016 ident: 10.1016/S2055-6640(20)30043-1_bb0075 article-title: Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients publication-title: Hepatology doi: 10.1002/hep.28625 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0165 – volume: 308 start-page: 2584 year: 2012 ident: 10.1016/S2055-6640(20)30043-1_bb0035 article-title: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis publication-title: JAMA doi: 10.1001/jama.2012.144878 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0155 – volume: 64 start-page: 1711 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0115 article-title: Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice publication-title: Clin Infect Dis doi: 10.1093/cid/cix111 – volume: 64 start-page: 1721 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0120 article-title: Real-world effectiveness of DAA therapies in human immunodeficiency virus/hepatitis C virus coinfection: 996 veterans can't be wrong publication-title: Clin Infect Dis doi: 10.1093/cid/cix117 – volume: 49 start-page: 1605 year: 2009 ident: 10.1016/S2055-6640(20)30043-1_bb0200 article-title: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression publication-title: Clin Infect Dis doi: 10.1086/644771 – volume: 313 start-page: 1223 year: 2015 ident: 10.1016/S2055-6640(20)30043-1_bb0100 article-title: Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial publication-title: JAMA doi: 10.1001/jama.2015.1328 – volume: 67 start-page: 847 year: 2018 ident: 10.1016/S2055-6640(20)30043-1_bb0135 article-title: Hepatitis C and human immunodeficiency virus co-infection in the era of direct-acting antiviral agents: no longer a difficult to treat population publication-title: Hepatology doi: 10.1002/hep.29642 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0170 – volume: 62 start-page: 1353 year: 2015 ident: 10.1016/S2055-6640(20)30043-1_bb0020 article-title: Toward a more accurate estimate of the prevalence of hepatitis C in the United States publication-title: Hepatology doi: 10.1002/hep.27978 – volume: 16 start-page: 797 year: 2016 ident: 10.1016/S2055-6640(20)30043-1_bb0025 article-title: Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00485-5 – volume: 4 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0130 article-title: Highly successful hepatitis C virus (HCV) treatment outcomes in human immunodeficiency virus/HCV-coinfected patients at a large, urban, Ryan White clinic publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofx062 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0055 – volume: 22 start-page: 481 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0080 article-title: Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients publication-title: Antivir Ther doi: 10.3851/IMP3117 – volume: 5 year: 2018 ident: 10.1016/S2055-6640(20)30043-1_bb0205 article-title: Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofx264 – volume: 65 start-page: 426 year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0065 article-title: The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection publication-title: Hepatology doi: 10.1002/hep.28901 – year: 2018 ident: 10.1016/S2055-6640(20)30043-1_bb0185 publication-title: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C – year: 2018 ident: 10.1016/S2055-6640(20)30043-1_bb0015 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0145 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0180 publication-title: Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment guidance for industry – volume: 373 start-page: 714 year: 2015 ident: 10.1016/S2055-6640(20)30043-1_bb0105 article-title: Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1503153 – volume: 30 start-page: 787 year: 1999 ident: 10.1016/S2055-6640(20)30043-1_bb0045 article-title: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group publication-title: Hepatology doi: 10.1002/hep.510300319 – year: 2017 ident: 10.1016/S2055-6640(20)30043-1_bb0160 – volume: 158 start-page: 658 year: 2013 ident: 10.1016/S2055-6640(20)30043-1_bb0195 article-title: HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study publication-title: Ann Intern Med doi: 10.7326/0003-4819-158-9-201305070-00604 |
| SSID | ssib050734121 ssj0001634228 |
| Score | 2.1094933 |
| Snippet | Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for... Objectives: Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 138 |
| SubjectTerms | clinical trial Food and Drug Administration hepatitis C Original Research |
| Title | Sustained virological response rates with direct‐acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31700657 https://www.proquest.com/docview/2313378951 https://pubmed.ncbi.nlm.nih.gov/PMC6816118 https://doaj.org/article/ea8c4e0d9fe1416b902f04c01f7922f3 |
| Volume | 5 |
| WOSCitedRecordID | wos000494965700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2055-6659 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001634228 issn: 2055-6640 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2055-6659 dateEnd: 99991231 omitProxy: false ssIdentifier: ssib050734121 issn: 2055-6640 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELag4sAFgXgFSmUkDnAI9SuxzY1WrXqhQiqgvVnxC1aqstVmlyM_hF_bsZ1NdyukXrgkkmMnlj32fBnPfIPQOyp9pFHrmnopaxG8rW3wvAbN4GJjnfBNSTYhz8_VbKa_bqX6Sj5hhR64DNxh6JQTgXgdAwXwYDVhkQhHaJSasZh5PgH1bP1MgSQByIHdOQddMdI0ddsKchO-c3gxFb5n5APPJ9B0RzFl_v5_gc7bvpNbyuj0MXo0okj8ufT-CboX-qfo70UJhgoep-C1cVPDy-IFG3AihRhwMrziosjqFNTQ_8QwuPPk63s54HmPbTLp4WFtk4VmrH92_AMnNtdksMUUbzy4-k_4hgkaXlP4TfAi4k3AJc5ZQYZn6Pvpybfjs3pMvVA7IeWqdl3oiIpWB68ds623intplW2jjKR1hFnVCMcaTqywlHdESO4Ftx1oQt9Z_hzt9Ys-vERYe9CHVnhPUxCr5DZECZiNtbHt4K4qJDbjbtzIS57SY1yayQEtTZdJ02UYMXm6DK3Qx6nZVSHmuKvBUZrUqXLi1c4FIG1mlDZzl7RV6O1GJAysw3S40vVhsR4M4GTOpQLAWqEXRUSmT_FEgtg2skJyR3h2-rL7pJ__ylzfrQJITtWr_9H51-ghwL3sIUfVPtpbLdfhDXrgfq_mw_IA3ZczdZCXEVy__Dm5Bp2hIjI |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+virological+response+rates+with+direct-acting+antivirals+in+black+subjects+with+HCV+genotype+1+infection%3A+systematic+analysis+of+clinical+trials&rft.jtitle=Journal+of+virus+eradication&rft.au=Struble%2C+Kimberly&rft.au=Chan-Tack%2C+Kirk&rft.au=Qi%2C+Karen&rft.au=Valappil%2C+Thamban&rft.date=2019-09-18&rft.issn=2055-6640&rft.volume=5&rft.issue=3&rft.spage=138&rft_id=info:doi/10.1016%2FS2055-6640%2820%2930043-1&rft_id=info%3Apmid%2F31700657&rft.externalDocID=31700657 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-6640&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-6640&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-6640&client=summon |